12:00 AM
Aug 19, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Therascreen EGFR Mutation Detection Kit RGQ regulatory update

The U.K.'s NICE issued guidance recommending the use of 5 diagnostics methods, including 2 tests to detect EGFR mutations in patients with previously untreated, locally advanced or metastatic non-small cell lung cancer (NSCLC). NICE backed the cobas EGFR...

Read the full 180 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >